How long do you need to continue taking ceritinib/ceritinib (Zanda) and the reference course of treatment?

Ceritinib (Ceritinib) is an oral ALK tyrosine kinase inhibitor, mainly used to treat< /span>ALKpositive non-small cell lung cancer (NSCLC) patients are especially suitable for patients who are resistant to crizotinib or cannot tolerate crizotinib. Its mechanism of action is to prevent tumor cell proliferation and survival by selectively inhibiting the ALK signaling pathway, thereby delaying disease progression. In clinical use, ceritinib, as a targeted drug, usually needs to be taken for a long time to maintain the therapeutic effect.

Seritinib is generally administered orally once daily as a long-term maintenance model until disease progression or intolerable serious adverse reactions occur. Unlike chemotherapy, the course of targeted drug treatment has no fixed endpoint and is mainly determined based on the imaging evaluation of the tumor and the patient's overall tolerance. Patients should strictly follow the doctor's instructions during use and should not stop taking the medicine or change the dose at will to avoid tumor recurrence or drug resistance.

In actual clinical practice, the length of the course of ceritinib will vary depending on the patient's condition, tumor burden, previous treatment history and tolerance. Some patients with early relapse may need to continue taking the drug for more than a year, while patients with late stage or multiple treatment failures may need to continue taking the drug for several years. Doctors usually evaluate tumor shrinkage or stabilization based on CT or PET-CT imaging, and combine hematological indicators and quality of life to make individualized adjustments to the course of treatment.

During long-term use of ceritinib, patients should regularly review blood routine, liver function and electrocardiogram to detect potential side effects in a timely manner. At the same time, attention should be paid to adverse reactions such as gastrointestinal reactions, abnormal liver function, and interstitial lung disease, and dose adjustments or symptomatic treatment should be performed under the guidance of a doctor. Establishing a standardized medication management and follow-up system can help patients complete treatment safely and effectively, and achieve the goals of extending progression-free survival and improving quality of life.

Reference materials:https://www.drugs.com/